Related references
Note: Only part of the references are listed.An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19
Dafydd R. Owen et al.
SCIENCE (2021)
The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY
Simon D. Harding et al.
NUCLEIC ACIDS RESEARCH (2018)
Mechanisms and Predictions of Drug-Drug Interactions of the Hepatitis C Virus Three Direct-Acting Antiviral Regimen: Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir
Mohamad Shebley et al.
DRUG METABOLISM AND DISPOSITION (2017)
Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir
Rajeev M. Menon et al.
JOURNAL OF HEPATOLOGY (2015)
Review and management of drug interactions with boceprevir and telaprevir
Jennifer J. Kiser et al.
HEPATOLOGY (2012)
Present State of Immunosuppressive Therapy in Liver Transplant Recipients
Russell H. Wiesner et al.
LIVER TRANSPLANTATION (2011)
A Phenotype-Genotype Approach to Predicting CYP450 and P-Glycoprotein Drug Interactions With the Mixed Inhibitor/Inducer Tipranavir/Ritonavir
J. B. Dumond et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Blood concentrations of everolimus are markedly increased by ketoconazole
JM Kovarik et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Share Paper
